Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 13/20 | 0.48 |
| ▸ | CCND1 | P24385 | 13/20 | 0.48 |
| ▸ | CCND3 | P30281 | 13/20 | 0.48 |
| ▸ | CDK6 | Q00534 | 13/20 | 0.48 |
| ▸ | CCNE1 | P24864 | 12/20 | 0.45 |
| ▸ | CDK2 | P24941 | 12/20 | 0.45 |
| ▸ | CDK1 | P06493 | 7/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 7/20 | 0.43 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30906847 | 1.00 | CDK4 (0.48) | CDK4CCND1CCND3CDK6CCNE1 | |
| SCHEMBL30906863 | 0.92 | CCND3 (0.48) | CDK4CCND1CCND3CDK6CCNE1 | |
| SCHEMBL27213224 | 0.92 | CCND3 (0.48) | CDK4CCND1CCND3CDK6CCNE1 | |
| SCHEMBL27213178 | 0.91 | CDK4 (0.47) | CDK4CCND1CCND3CDK6CCNE1 | |
| SCHEMBL30906886 | 0.91 | CDK4 (0.47) | CDK4CCND1CCND3CDK6CCNE1 | |
| SCHEMBL27213123 | 0.88 | CCNE1 (0.51) | CDK4CCND1CCND3CDK6CCNE1 | |
| SCHEMBL30906814 | 0.88 | CCNE1 (0.51) | CDK4CCND1CCND3CDK6CCNE1 | |
| SCHEMBL27213164 | 0.88 | CCNE1 (0.59) | CDK4CCND1CCND3CDK6CCNE1 | |
| SCHEMBL30906853 | 0.87 | CCNE1 (0.51) | CDK4CCND1CCND3CDK6CCNE1 | |
| SCHEMBL27213213 | 0.87 | CCNE1 (0.51) | CDK4CCND1CCND3CDK6CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150340-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2024-05-09 | — | — | US | claimed |
| WO-2024077216-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-04-11 | — | — | WO | claimed |
| US-20240150340-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2024-05-09 | — | — | US | disclosed |
| WO-2024077216-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150340-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK1, CDK3 | CDK4 12/4885CCND1 46/4885CCND3 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.